Application (EFSA‐GMO‐RX‐MS8‐RF3) for renewal of the authorisation for continued marketing of existing (1) food and food ingredients produced from genetically modified glufosinate‐tolerant oilseed rape Ms8, Rf3 and Ms8 × Rf3, and (2) feed materials produced from genetically modified glufosinate‐tolerant oilseed rape Ms8, Rf3 and Ms8 × Rf3, under Regulation (EC) No 1829/2003 from Bayer CropScience

Abstract Hybrid oilseed rape Ms8 × Rf3 has been produced by conventional crossing between the genetically modified (GM) parental lines Ms8 and Rf3. The hybrid system is achieved using a pollination control system by insertion and expression of barnase and barstar genes into two separate oilseed rape lines; each gene is linked to the bar gene conferring tolerance to glufosinate‐containing herbicides. The scope of this application covers the continued marketing of existing food (processed oil) and feeds produced from oilseed rape Ms8, Rf3 and Ms8 × Rf3 which were lawfully placed on the market in the Community before the date of entry into force of Regulation (EC) No 1829/2003. In 2005 the EFSA GMO Panel had issued a scientific opinion on the safety of glufosinate‐tolerant oilseed rape Ms8 × Rf3 derived from parental lines Ms8 and Rf3 for import and processing for feed and industrial uses. In delivering the present opinion, the EFSA GMO Panel considered the information provided in the application EFSA‐GMO‐RX‐MS8‐RF3 as well as additional information submitted by the applicant. The new data included molecular and bioinformatic analyses and a 42‐day feeding study on chickens. The animal study showed that the tested material of oilseed rape Ms8 × Rf3 was nutritionally equivalent to its non‐GM counterpart. In addition, bioinformatic studies using updated databases confirmed that no relevant similarities exist between the newly expressed proteins and known allergens or toxic proteins. Therefore, the EFSA GMO Panel reiterates the conclusions of its previous scientific opinion of 2005 that GM oilseed rape Ms8, Rf3 and Ms8 × Rf3 is unlikely to have an adverse effect on human and animal health or, in the context of its proposed uses, on the environment. This also applies to the products which are the subject of the present application.

Abstract licence: CC BY-ND

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.